Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Passes Below 200-Day Moving Average of $0.71

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBOGet Rating)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.71 and traded as low as $0.57. Northwest Biotherapeutics shares last traded at $0.60, with a volume of 998,669 shares.

Northwest Biotherapeutics Stock Up 4.2 %

The stock has a market cap of $657.39 million, a price-to-earnings ratio of -6.05 and a beta of -0.09. The stock’s 50 day moving average price is $0.58 and its two-hundred day moving average price is $0.71.

Northwest Biotherapeutics (OTCMKTS:NWBOGet Rating) last released its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($0.03) earnings per share for the quarter. The business had revenue of $0.60 million during the quarter. Northwest Biotherapeutics had a negative return on equity of 50.86% and a negative net margin of 4,697.69%.

Northwest Biotherapeutics Company Profile

(Get Rating)

Northwest Biotherapeutics, Inc is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L.

Featured Stories

Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with's FREE daily email newsletter.